5326602025-07-012025-09-305326602025-09-305326602025-03-315326602025-04-012025-09-305326602025-07-012025-09-30in-capmkt:OtherExpenses1Member5326602025-04-012025-09-30in-capmkt:OtherExpenses1Member5326602025-07-012025-09-30in-capmkt:ReportableSegments1Member5326602025-04-012025-09-30in-capmkt:ReportableSegments1Member5326602025-07-012025-09-30in-capmkt:ReportableSegments1Member5326602025-04-012025-09-30in-capmkt:ReportableSegments1Member5326602025-07-012025-09-30in-capmkt:ReportableSegments1Member5326602025-09-30in-capmkt:ReportableSegments1Member5326602025-07-012025-09-30in-capmkt:ReportableSegments1Member5326602025-09-30in-capmkt:ReportableSegments1Member5326602025-07-012025-09-30AuditorDomain15326602025-07-012025-09-30in-capmkt:AuditedMember5326602025-09-30in-capmkt:AuditedMember5326602025-07-012025-09-30in-capmkt:AdjustedMember5326602025-09-30in-capmkt:AdjustedMember5326602025-07-012025-09-30AuditQualification1iso4217:INRiso4217:INRxbrli:shares532660VIVIMEDLABnaINE526G01021Vivimed Labs LimitedMain BoardEquity2025-04-012026-03-312025-11-132025-10-28INRMillionsQuarterlySecond quarterGeographical2025-11-1316:00:002025-11-1319:00:00trueCash Flow DirectStatement on impact of audit qualificationtruefalseNoNofalsetrue2022-04-28https://www.vivimedlabs.com/wp-content/uploads/2021/09/Related-Party-Transactions-Policy.pdffalsetrue2025-07-012025-09-30UnauditedStandalone18659000016000001881900006012000003816000045830000160100004684000055680000262640000-744500000-744500000000-744500000000-744500000-7445000000-0.9-0.8700-0.9-0.87NOTES <BR> 1. The above standalone financial results of Vivimed Labs Limited ("the Company") as reviewed by the Audit Committee has been approved by the Board of Directors at its meeting held on November 13, 2025. The statutory auditors of the Company have carried out a limited review on standalone financial results and expressed modified conclusion thereon.. <BR> 2. These standalone financial results of the Company have been prepared in accordance with the Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder ('IND AS') and other accounting principles generally accepted in India and guidelines issued by the Securities and Exchange Board of India ("SEBI"). <BR> 3. Working capital loan availed from SBI bank has been assigned to Rare Asset Reconstruction Company (ARC) under the SARFAESI Act, 2002. The liability continues to be shown under Borrowings and is payable to Rare ARC <BR> 4.Deferred tax will be calculated at the end of year. <BR> 5. Corresponding numbers of previous period / year have been regrouped, wherever necessary. <BR> <BR> 2025-04-012025-09-30UnauditedStandalone3660200005200000371220000161260000028410000909300002123000094800000104000000500630000-1294100000-1294100000000-1294100000000-1294100000-12941000000-1.56-1.5200-1.56-1.52Other Expenses55680000Other Expenses10400000023866100001711300001691400004932000005877300000587730000380781000050057000005755100005920000035350000479720000109650000099010000895720000259180000063996100001658300002901800004560100004560100006330600001071220000170428000040170000903300005220000184000000031170500000395340000395340000217500003534140000279000000110430000180030000410360000059436000006399610000sale0sale00000sale0sale000000000sale0000sale0000-1175000000000-76030000-58890000000034230000-1688700000-212300000-69000048690000-9826000000000011250000001000000000000000000000001126000000000000018900000002123000000-19340000-50000000-50000001092000059200000000UnauditedQualified opinionsvrl&cotrue2027-04-30188190000188190000262640000419920000-74450000-231730000-0.9-2.796399610000639961000063996100006399610000456010000148900000Based on information provided to us by management, Vivimed Labs Limited has not provided for interest expenses of 157.28 million on an accrual basis, pertaining to loans [Term Loans and Working capital Loans]. This omission results in an understatement of liabilities and losses for the reporting period, thereby deviating the accrual principle as mandated by Indian accounting standardsQualified opinionRepetitivenanananaSantosh VaralwarPhanindernath PetasontiJarugula Siva PrasadG RamakrishnaHyderabad2025-11-1343839600000000